TP
SLDB icon

Tranquility Partners’s Solid Biosciences SLDB Stock Holding History

Tranquility Partners’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000
Closed -$7K – 215
2022
Q3 		$7K Buy
+1,000
New +$10.1K ﹤0.01% 189

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tranquility Partners's SLDB Position: Q4 2022 in Review

Tranquility Partners sold out of Solid Biosciences (SLDB) in Q4 2022, closing a stake of 1,000 shares — an estimated $7K sold.

Tranquility Partners first reported a position in SLDB in Q3 2022 and held it in 1 quarter. The position peaked at $7K in Q3 2022. 35 funds tracked by Wall St. Rank hold SLDB as of Q4 2022.

  • Tranquility Partners reported no remaining Solid Biosciences position as of Q4 2022 after selling out during the quarter.
  • Tranquility Partners sold 1,000 Solid Biosciences shares in Q4 2022, an estimated $7K.
  • Tranquility Partners first reported a position in Solid Biosciences in Q3 2022 and held it in 1 quarter.
  • Tranquility Partners's Solid Biosciences position peaked at $7K in Q3 2022.
  • 35 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2022.

Based on Tranquility Partners's 13F filing for Q4 2022, filed 2 Feb 2023.